Kineta, the Seattle-based developer of treatments for autoimmune diseases, said it has received a two-year, $600,000 grant from the National Institutes of Health to do work that could enable clinical trials of a new drug for Type 1 diabetes, multiple sclerosis and other autoimmune diseases. Kineta said it plans to start clinical trials on the drug in the second half of 2010.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
